These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

552 related items for PubMed ID: 17931151

  • 1. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.
    O'Hagan DT.
    Expert Rev Vaccines; 2007 Oct; 6(5):699-710. PubMed ID: 17931151
    [Abstract] [Full Text] [Related]

  • 2. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
    Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R, Family Medicine Group of Pianiga.
    Vaccine; 2007 May 16; 25(20):3955-61. PubMed ID: 17383057
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A.
    Pediatr Infect Dis J; 2009 Jul 16; 28(7):563-71. PubMed ID: 19561422
    [Abstract] [Full Text] [Related]

  • 5. MF59 adjuvant: the best insurance against influenza strain diversity.
    O'Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G.
    Expert Rev Vaccines; 2011 Apr 16; 10(4):447-62. PubMed ID: 21506643
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?
    O'Hagan DT, Wack A, Podda A.
    Clin Pharmacol Ther; 2007 Dec 16; 82(6):740-4. PubMed ID: 17971820
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].
    Li RC, Fang HH, Li YP, Liu YP, Nong Y, Huang GB.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun 16; 29(6):548-51. PubMed ID: 19040034
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.
    Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB.
    Clin Infect Dis; 2006 Nov 01; 43(9):1135-42. PubMed ID: 17029131
    [Abstract] [Full Text] [Related]

  • 13. Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis.
    Tsai T, Kyaw MH, Novicki D, Nacci P, Rai S, Clemens R.
    Vaccine; 2010 Feb 17; 28(7):1877-80. PubMed ID: 19969117
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.
    Ansaldi F, Zancolli M, Durando P, Montomoli E, Sticchi L, Del Giudice G, Icardi G.
    Vaccine; 2010 Jun 07; 28(25):4123-9. PubMed ID: 20433807
    [Abstract] [Full Text] [Related]

  • 16. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses.
    Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, Icardi G, Gasparini R, Crovari P.
    Vaccine; 2008 Mar 17; 26(12):1525-9. PubMed ID: 18294741
    [Abstract] [Full Text] [Related]

  • 17. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
    Radosević K, Rodriguez A, Mintardjo R, Tax D, Bengtsson KL, Thompson C, Zambon M, Weverling GJ, Uytdehaag F, Goudsmit J.
    Vaccine; 2008 Jul 04; 26(29-30):3640-6. PubMed ID: 18514980
    [Abstract] [Full Text] [Related]

  • 18. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile.
    Podda A, Del Giudice G.
    Expert Rev Vaccines; 2003 Apr 04; 2(2):197-203. PubMed ID: 12899571
    [Abstract] [Full Text] [Related]

  • 19. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.
    Black S, Della Cioppa G, Malfroot A, Nacci P, Nicolay U, Pellegrini M, Sokal E, Vertruyen A.
    Vaccine; 2010 Oct 21; 28(45):7331-6. PubMed ID: 20813217
    [Abstract] [Full Text] [Related]

  • 20. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects.
    Gasparini R, Schioppa F, Lattanzi M, Barone M, Casula D, Pellegrini M, Veitch K, Gaitatzis N.
    Int J Clin Pract; 2010 Mar 21; 64(4):432-8. PubMed ID: 20039974
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.